Heparin/lidocaine/sodium bicarbonate

Drug Profile

Heparin/lidocaine/sodium bicarbonate

Alternative Names: Alkalised lidocaine and heparin formulation - Urigen Pharmaceuticals; Compounded alkalinised lidocaine and heparin - Imprimis; Hep-Lido-A compounded formulation; U 101; URG-101

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Urigen Pharmaceuticals
  • Class Acetanilides; Alkalinising agents; Heparins; Local anaesthetics; Small molecules; Urologics
  • Mechanism of Action Factor Xa inhibitors; Sodium channel antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Interstitial cystitis
  • Discontinued Cystitis; Dyspareunia

Most Recent Events

  • 18 May 2015 Efficacy and pharmacokinetics data from a clinical trial in Interstitial cystitis released by Imprimis Pharmaceuticals
  • 08 May 2015 Imprimis has patent protection for heparin/lidocaine/sodium bicarbonate compounded formulation in USA
  • 28 Apr 2015 Imprimis notified Urigen of its intent to convert its commercial rights of heparin/lidocaine/sodium bicarbonate to exclusive
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top